Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cognition TherapeuticsCGTX -1.98%32 EV-to-OCF is -3.43 as of Sep. 10, 2026. GuruFocus rates CGTX with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,404 Biotechnology companies, Cognition Therapeutics ranks worse than 50.21% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cognition Therapeutics's Enterprise Value is $60.72 Mil.
Cognition Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-17.68 Mil. Therefore, Cognition Therapeutics's EV-to-OCF for today is -3.43.
The historical rank and industry rank for Cognition Therapeutics's EV-to-OCF or its related term are showing as below:
CGTX'
s EV-to-OCF Range Over the Past 10 Years
Min: -3.65 Med: 0 Max: -3.41
Current: -3.43
During the past 7 years, the highest EV-to-OCF of Cognition Therapeutics was -3.41. The lowest was -3.65. And the median was .
CGTX's EV-to-OCF is ranked worse than 50.21% of 1404
companies
in the Biotechnology industry
Industry Median: -3.45
vs CGTX: -3.43
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cognition Therapeutics's PE Ratio (TTM) for today is calculated as:
Cognition Therapeutics's share price for today is $0.9927.
Cognition Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cognition Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cognition Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cognition Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cognition Therapeutics's EV-to-OCF falls into.
Cognition Therapeutics's current Enterprise Value is $60.72 Mil.
Cognition Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cognition Therapeutics (CGTX) has a EV-to-OCF of -3.43 as of Sep. 10, 2026. According to the industry distribution chart, Cognition Therapeutics ranks #705 out of 1404 companies in the Biotechnology industry, placing it in the top 50.2%.
Is Cognition Therapeutics' EV-to-OCF too high?
Cognition Therapeutics' current EV-to-OCF is -3.43. Based on the distribution chart, Cognition Therapeutics ranks #705 out of 1404 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cognition Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Cognition Therapeutics' EV-to-OCF compare to RANI and VRCA?
According to the Biotechnology industry distribution chart, Cognition Therapeutics ranks #705 out of 1404 companies for EV-to-OCF. This places Cognition Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Cognition Therapeutics's current EV-to-OCF is -3.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cognition Therapeutics stock overvalued right now?
Cognition Therapeutics (CGTX) has a current EV-to-OCF of -3.43. The current EV-to-OCF is -3.43. Cognition Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cognition Therapeutics (CGTX), the current EV-to-OCF is -3.43 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
32GF Score
Get the complete analysis for CGTX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGTX has been successfully added to your 
